Inter-rater agreement on chromosome 5 breakage in FISH-based mutagen sensitivity assays (MSAs)

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 562, Issue 1-2, 2004, Pages 133-142

  Barker, Peter E ^a   Wang, Wendy ^b   Wagner, Paul D ^b   Pinsky, Paul ^b  

^a NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Early Detection Research Network; EDRN; FISH; M. D. Anderson Cancer Center; MDACC; MSA; mutagen sensitivity assay; National Cancer Institute; National Institute of Standards and Technology, US Department of Commerce; NCI; NIST

Indexed keywords

MUTAGENIC AGENT;

ARTICLE; CELL SELECTION; CHROMOSOME 5; CHROMOSOME BREAKAGE; CYTOGENETICS; DATA ANALYSIS; EDUCATION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMAGING; MEASUREMENT; NORMAL HUMAN; OBSERVER VARIATION; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; VALIDATION PROCESS; VOLUNTEER;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 5; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTAGENS; OBSERVER VARIATION;

EID: 3242785702     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2004.06.001     Document Type: Article

References (34)

1. Wood R.D., Mitchell M., Sgouros J., Lindahl T. Human DNA repair genes. Science. 291:2001;1284-1289
2. Berwick M., Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiological review. J. Natl. Cancer Inst. 92:2001;874-897
3. Nowak M.A., Komarova N.L., Sengupta A., Jallepalli P.V., Shih I.M., Vogelstein B., Lengauer C. The role of chromosome instability in tumor initiation. Proc. Natl. Acad. Sci. USA. 99:2002;16226-16231
4. Hsu T.C., Spitz M.R., Schantz S.P. Mutagen sensitivity: a biological marker of cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 1:1991;83-89
5. Trenz K., Lugowski S., Jahrsdoefer U., Jainta S., Vogel W., Speit G. Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards mutagenic effects of various cytostatics. Mutat. Res. 544:2003;279-288
6. Moller P., Knudson L.E., Loft S., Wallin H. The comet assay as a rapid test in biomonitoring occupational exposure to DNA-damaging agents and effect of confounding factors. Cancer Epidemiol. Biomarkers Prev. 9:2000;1005-1015
7. Wienke J.K., Christiani D.C., Kelsey K.T. Bimodal distribution of sensitivity to SCE induction by diepoxybutane in human lymphocytes. I. Correlation with chromosomal aberrations. Mutat. Res. 248:1991;17-26
8. Hsu T.C. Genetic instability in human populations: a working hypothesis. Hereditas. 98:1983;1-9
9. Cherry L.M., Hsu T.C. Bleomycin-induced chromosome damage in lymphocytes of medullary thyroid carcinoma patients and their family members. Anticancer Res. 3:1983;367-372
10. Hsu T.C., Cherry L.M., Samaan N. Differential mutagen sensitivity in cultured lymphocytes of normal individuals and cancer patients. Cancer Genet. Cytogenet. 17:1985;305-313
11. Suzuki H., Nagai K., Yamaki H., Tanaka N., Umezawa H. On the mechanism of bleomycin: scission of DNA strand in vitro and in vivo. J. Antibiot. (Tokyo). 22:1969;446-448
12. Zheng Y.L., Loffredo C.A., Zhipeng Y., Jones R.T., Krasna M.J., Alberg A.J., Yung R., Perlmutter D., Enewold L., Harris C.C., Shields P.G. Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. Carcinogenesis. 24:2003;269-274
13. Hsu T.C., Johnson D.J., Cherry L.M., Ramkinsson D., Schantz S.P., Jessup J.M., Winn L.J., Shirley L., Furlong C. Sensitivity to genotoxic effects of bleomycin in humans: possible relationship to environmental carcinogenesis. Int. J. Cancer. 43:1989;403-409
14. Gu J., Bondy M.L., Sigurdson A., Spitz M.R., Hsu T.C., Wu X. Three measures of mutagen sensitivity in a cancer-free population. Cancer Genet. Cytogenet. 110:1999;65-69
15. Hibi K., Takahashi T., Yamakawa K., Ueda R., Sekido Y., Ariyoshi Y., Suyama M., Takagi H., Nakamura Y., Takahashi T. Three distinct regions involving 3p deletions in human lung cancer. Oncogene. 7:1992;445-449
16. Ohta M., Inoue H., Cotticelli M.G., Kastury K., Baffa R., Palazzo J., Siprashvili Z., Mori M., McCue P., Druck T., Croce C.M., Huebner K. The FHTI gene, spanning the chromosome 3p14.2 fragile site and renal cell carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 84:1996;587-597
17. Wu X., Zhao Y., Honn W.K., Spitz M.R. Benzo[a]pyrene diol epoxide-induced 3p21.3 aberrations and genetic predisposition to lung cancer. Cancer Res. 58:1998;1605-1608
18. Wu X., Hsu T.C., Annegers J.F., Amos C.I., Fueger J.J., Spitz M.R. A case-control study of nonrandom distribution of bleomycin-induced chromatid breaks in lymphocytes of lung cancer patients. Cancer Res. 55:1995;557-561
19. Venter J.C., et al. The sequence of the human genome. Science. 291:2001;1-60
20. O'Neill R.R., Mitchell L.G., Merril C.R., Rasband W.S. Use of image analysis to quantitate changes in form of mitochondrial DNA after X-irradiation. Appl. Theoret. Electrophor. 1:1989;163-167
21. Fleiss J.L., Spitzer R.L., Endicott J., Cohen J. Quantification of agreement in multiple psychiatric diagnosis. Arch. Gen. Psychiatr. 26:1972;168-171
22. Srivastava S., Rossi S.C. Early detection research program at the NCI. Int. J. Cancer. 69:1996;35-37
23. Verma M., Srivastava S. New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res. 163:2003;72-84
24. Barker P.E. Cancer biomarker validation, standards and process: roles for the National Institute of Standards and Technology. Ann. NY Acad. Sci. 983:2002;142-150
25. Moore D.H., Epstein L., Reeder J., Wheeless L., Waldman F.M. Interlaboratory variability in fluorescence in situ hybridization hybridization analysis. Cytometry. 25:1996;125-132
26. Bonassi S., Hagmar L., Stromberg U., Montagud A.H., Tinnerberg H., Forni A., Heikkila P., Wanders S., Wilhardt P., Hansteen I.-L., Knudsen L.E., Noruppa H. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. Cancer Res. 60:2000;1619-1625
27. A. Aitio, G. Becking, A. Berlin, A. Bernard, V. Foa, D. Kello, E. Krug, A. Leonard, G. Nordberg, Indicators for assessing exposure and biological effects of genotoxic chemicals. Consensus and technical reports. Commission of the European Communities, International Programme on Chemical Safety (UNEP-ILO-WHO), World Health Organization, Regional Office for Europe, Institute of Occupational Health, Finland, 1988.
28. International Commission for protection against Environmental Mutagens and Carcinogens, Considerations for population monitoring using cytogenetic techniques. Mutat. Res. 204 (1998) 379-406.
29. Au W.W. Mutagen sensitivity assays in population studies. Mutat. Res. 544:2003;273-277
30. McIntyre L.M., O'Briant K., McBride C.M., Bepler G. Rater agreement and utility of the mutagen-induced chromosome damage assay. Anticancer Res. 21:2001;605-610
31. Gabor S., Eva R., Kasler M., Andrea B. Validity of chromosomal analysis and bleomycin sensitivity assay in prevention of head and neck cancer. Orvosi. Hetilap. 142:2001;611-616
32. Szekely E., Remenar E., Kasler M., Gundy S. Does the bleomycin sensitivity assay express cancer phenotype. Mutagenesis. 18:2003;59-63
33. Wei Q., Spitz M.R., Gu J., Cheng L., Wu X., Strom S.S., Kripke M.L., Hsu T.C. DNA repair capacity correlates with mutagen sensitivity in lymphoblastoid cells lines. Cancer Epidemiol. Biomarkers Prev. 5:1996;199-204
34. Hsu T.C., Shillitoe E.J., Cherry L.M., Lin Q., Schantz S.P., Furlong C. Cytogenetic characterization of 20 lymphoblastoid lines derived from human individuals differing in bleomycin sensitivity. In Vitro Cell. Dev. 26:1990;80-84